NCT05522075 Reducing Blood Pressure in Mid-life Adult Binge Drinkers
| NCT ID | NCT05522075 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Texas at Arlington |
| Condition | Alcohol Drinking |
| Study Type | INTERVENTIONAL |
| Enrollment | 55 participants |
| Start Date | 2022-11-21 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 55 participants in total. It began in 2022-11-21 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study has two phases: Phase 1 is to examine blood pressure, microvascular function, and sympathetic nerve activity in mid-life adult binge drinkers vs. alcohol abstainers/moderate drinkers. Phase 2 is to examine the effect of 8-week aerobic exercise training on blood pressure, microvascular function, and sympathetic nerve activity in mid-life adult binge drinkers
Eligibility Criteria
Inclusion Criteria: * Men and women (50-64 years of age) who do not drink alcohol, who drink at moderate levels, or who binge drink * Female subjects will be postmenopausal (i.e., cessation of menses for ≥1 yr). * Subjects who can speak and understand English. Exclusion Criteria: * a history of diabetes, cardiovascular disease, liver, or renal disease * current or history of smoking and illicit drug use * blood pressure ≥160/100 mm Hg * other known traditional cardiovascular disease risks: obesity (BMI≥35 kg/m2), or hyperlipidemia (total cholesterol\>230 mg/dl and/or LDL cholesterol\>160 mg/dl) * active infection (in the past 2 months) * a history of seizures, cancer, or inflammatory disease (i.e., gout or rheumatoid) * unstable body weight (\>5% change during the past 6 months) * regular aerobic exercise training (i.e., they engage in 30 min of structured aerobic exercise at least 3 times per week) * current use of hormone replacement therapy (i.e., estrogen, progesterone, and testosterone)
Contact & Investigator
Chueh-Lung Hwang, PhD
PRINCIPAL INVESTIGATOR
University of Texas at Arlington
Frequently Asked Questions
Who can join the NCT05522075 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 64 Years, studying Alcohol Drinking. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05522075 currently recruiting?
Yes, NCT05522075 is actively recruiting participants. Contact the research team at chuehlung.hwang@uta.edu for enrollment information.
Where is the NCT05522075 trial being conducted?
This trial is being conducted at Arlington, United States.
Who is sponsoring the NCT05522075 clinical trial?
NCT05522075 is sponsored by The University of Texas at Arlington. The principal investigator is Chueh-Lung Hwang, PhD at University of Texas at Arlington. The trial plans to enroll 55 participants.